Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

560 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D'Rozario J, Assouline S, Owen C, Gerecitano J, Robak T, De la Serna J, Jaeger U, Cartron G, Montillo M, Humerickhouse R, Punnoose EA, Li Y, Boyer M, Humphrey K, Mobasher M, Kater AP. Seymour JF, et al. N Engl J Med. 2018 Mar 22;378(12):1107-1120. doi: 10.1056/NEJMoa1713976. N Engl J Med. 2018. PMID: 29562156 Free article. Clinical Trial.
A phase II study of dexamethasone, ifosfamide, cisplatin and etoposide (DICE) as salvage chemotherapy for patients with relapsed and refractory lymphoma.
Biagi JJ, Herbert KE, Smith C, Abdi E, Leahy M, Falkson C, Wolf M, Januszewicz H, Seymour JF, Richards K, Matthews JP, Dale B, Prince HM. Biagi JJ, et al. Among authors: seymour jf. Leuk Lymphoma. 2005 Feb;46(2):197-206. doi: 10.1080/10428190400014884. Leuk Lymphoma. 2005. PMID: 15621802 Clinical Trial.
A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma.
Morschhauser F, Seymour JF, Kluin-Nelemans HC, Grigg A, Wolf M, Pfreundschuh M, Tilly H, Raemaekers J, van 't Veer MB, Milpied N, Cartron G, Pezzutto A, Spencer A, Reyes F, Dreyling M. Morschhauser F, et al. Among authors: seymour jf. Ann Oncol. 2008 Feb;19(2):247-53. doi: 10.1093/annonc/mdm463. Epub 2007 Sep 28. Ann Oncol. 2008. PMID: 17906297 Free article. Clinical Trial.
5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen.
O'Brien S, Moore JO, Boyd TE, Larratt LM, Skotnicki AB, Koziner B, Chanan-Khan AA, Seymour JF, Gribben J, Itri LM, Rai KR. O'Brien S, et al. Among authors: seymour jf. J Clin Oncol. 2009 Nov 1;27(31):5208-12. doi: 10.1200/JCO.2009.22.5748. Epub 2009 Sep 8. J Clin Oncol. 2009. PMID: 19738118 Free PMC article. Clinical Trial.
560 results